Medicine for treating heart of human body
By using pills composed of traditional Chinese medicines such as Danshen in specific proportions, the problems of side effects and unstable efficacy in existing drug treatments for heart disease have been solved, achieving effective treatment and improved absorption efficiency for heart disease.
Patent Information
- Application Number
- CN202511547278.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-28
- Publication Date
- 2025-12-12
AI Technical Summary
Current drug treatments for heart disease focus on symptom relief and risk factor control, but have side effects and drug resistance issues. Furthermore, traditional Chinese medicine formulas have complex ingredients and imprecise proportions, resulting in unstable efficacy and low absorption efficiency, making it difficult to meet modern clinical needs.
The pills are made from Chinese herbs such as Salvia miltiorrhiza, Allium macrostemon, Trichosanthes kirilowii seed, Polygala tenuifolia, Ophiopogon japonicus, Santalum album, Citrus reticulata peel, Lilium brownii, Platycladus orientalis seed, Poria cocos, Sakura powder, and Pheretima aspergillum in a specific ratio. Through steps such as pulverizing, stir-frying Pheretima aspergillum with wine, and mixing and making pills, the ingredients are clearly defined and the proportions are precise, thus achieving standardized production.
It significantly treats heart diseases such as coronary heart disease, myocardial ischemia, and arrhythmia, improves drug absorption efficiency and efficacy stability, and meets modern drug quality control standards.
Smart Images
Figure CN121102385A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the field of medicine, in particular to a medicine for treating human heart. BACKGROUND
[0002] Cardiovascular diseases, such as coronary heart disease, myocardial ischemia and arrhythmia, are one of the main diseases leading to death and disability at present. Although modern medicine has made significant progress in treating these diseases, including restoring blood flow or correcting heart rhythm through surgical methods (such as coronary stent implantation, radiofrequency ablation or pacemaker implantation), these treatment methods cannot completely cure the disease. Clinical studies have shown that even if the operation is successful, patients still face the risk of recurrence, progression or new vascular lesions and arrhythmia. In addition, postoperative management usually requires a combination of drug therapy, cardiac rehabilitation programs, lifestyle interventions and other measures, but a considerable proportion of patients are still affected by long-term survival due to disease progression, complications or other acute cardiovascular events. According to statistics, in patients with severe coronary heart disease or heart failure, patients may face the risk of death after diagnosis, and the specific survival rate depends on the severity of the disease, treatment compliance and overall health status. The existing technology has the following problems: Existing drug therapy focuses on symptom relief and risk factor control, such as anti-platelet drugs, beta blockers, ACE inhibitors, etc., but these drugs often have side effects, drug resistance problems, and cannot fundamentally repair heart function. Traditional Chinese medicine and other traditional prescriptions usually have complex ingredients, inaccurate proportions, lack of standardized preparation process, resulting in unstable efficacy, low absorption efficiency, and difficulty in meeting modern clinical needs; Therefore, it is of great clinical significance and social value to develop a traditional Chinese medicine preparation with clear ingredients, scientific proportions, standardized preparation and effective treatment of coronary heart disease, myocardial ischemia and arrhythmia and other heart diseases. SUMMARY
[0003] The main purpose of the present application is to provide a medicine for treating human heart, which can effectively solve the problems of existing drug therapy focusing on symptom relief and risk factor control, having side effects, drug resistance problems, and being unable to fundamentally repair heart function; and traditional Chinese medicine prescriptions having complex ingredients, inaccurate proportions, lack of standardized preparation process, resulting in unstable efficacy, low absorption efficiency, and difficulty in meeting modern clinical needs.
[0004] To achieve the above-mentioned purpose, the technical scheme adopted by the present application is: A medicine for treating human heart, which is composed of the following components in mass percentage: 13.8% of Danshen, 4.1% of Xiebai, 8.3% of Gualouren, 2% of Yuanzhi, 8.3% of Maidong, 2% of Tanshang, 6.9% of Qingpi, 13.8% of Baihe, 8.3% of Baiziren, 10.4% of Fuling, 8.3% of Yinghuafen and 13.8% of Dilong, and the sum of the mass percentages of the above components is 100%.
[0005] Preferably, the dosage form of the medicine composition is pill.
[0006] A preparation method of a medicine for treating human heart, which is used for preparing the medicine for treating human heart as described above, and comprises the following steps: S1: separately taking prescribed amounts of Danshen, Xiebai, Gualouren, Yuanzhi, Maidong, Tanshang, Qingpi, Baihe, Baiziren, Fuling, Yinghuafen, crushing and sieving to obtain mixed medicine powder; S2: taking prescribed amount of Dilong, frying with wine, crushing and sieving to obtain Dilong powder; S3: fully mixing the mixed medicine powder obtained in step S1 with the Dilong powder obtained in step S2, and using existing pill-making technology to prepare pills.
[0007] Preferably, the specific process of frying with wine in step S2 is as follows: evenly mixing Dilong with yellow wine, and moistening until the wine is absorbed, then frying with small fire until the surface is brown, and taking out and cooling.
[0008] Preferably, the mesh number of the medicine sieve used for crushing and sieving in steps S1 and S2 is 80-120 mesh.
[0009] Preferably, after step S3, the prepared pills are packaged according to single dose.
[0010] Preferably, the medicine composition for treating human heart disease is used for treating coronary heart disease.
[0011] Preferably, the medicine composition for treating human heart disease is used for treating myocardial ischemia.
[0012] Preferably, the medicine composition for treating human heart disease is used for treating arrhythmia.
[0013] Preferably, the medicine composition for treating human heart disease is used for relieving angina pectoris, palpitation or palpitation.
[0014] Compared with the prior art, the present application has the following beneficial effects: 1. The present application provides a kind of medicine for treating human heart, by salvia miltiorrhiza, Chinese onion, trichosanthes fruit, polygala, ophiopogon, sandalwood, green skin, lily, cypress seed, tuckahoe, sakura powder, earthworm and other above-mentioned traditional Chinese medicine decoction pieces according to its corresponding formula proportion and process are pulverized and matched, make it play the maximum efficacy of all decoction pieces, more easily taken and absorbed, after taking, it can have obvious therapeutic effect on the problems such as myocardial blood supply insufficiency, dyspnea, weakness, fatigue, angina pectoris, palpitation, heart palpitations caused by heart of heart disease patients, can effectively treat coronary heart disease, myocardial ischemia, arrhythmia and other heart diseases.
[0015] 2. The present application provides a kind of medicine for treating human heart, by salvia miltiorrhiza, Chinese onion, trichosanthes fruit, polygala, ophiopogon, sandalwood, green skin, lily, cypress seed, tuckahoe, sakura powder and earthworm are composed of specific mass percentage, and through the steps such as crushing, screening, wine stir-fried earthworm, mixing pill, realize standardization production, the process ensures the dissolution and absorption of effective components, overcome the unstable curative effect, big batch difference caused by the complex composition, inaccurate proportion of traditional Chinese medicine preparation, meet modern pharmaceutical quality control standards. BRIEF DESCRIPTION OF DRAWINGS
[0016] Figure 1 The preparation process of the medicine of the present application is shown in the figure. DETAILED DESCRIPTION
[0017] In order to make the technical means, creative features, purposes and effects realized by the present application easy to understand, the present application is further described below in combination with specific embodiments.
[0018] Example 1: typical preparation of pharmaceutical composition Raw material preparation: Based on the percentage of 13.8% of Danshen, 4.1% of Baiyun, 8.3% of Gualouren, 2% of Yuanzhi, 8.3% of Maidong, 2% of Tanshen, 6.9% of Qingpi, 13.8% of Baihe, 8.3% of Baiziren, 10.4% of Fuling, 8.3% of Yinghuafen, 13.8% of Dilong, for example, the total amount of 145 grams, accurately weigh each traditional Chinese medicine decoction piece, the specific quality is as follows: Danshen: 20.0g (calculated: 145g*13.8%), Baiyun: 5.9g (calculated: 145g*4.1%), Gualouren: 12.0g (calculated: 145g*8.3%), Yuanzhi: 2.9g (calculated: 145g*2.0%), Maidong: 12.0g (calculated: 145g*8.3%), Tanshen: 2.9g (calculated: 145g*2.0%), Qingpi: 10.0g (calculated: 145g*6.9%), Baihe: 20.0g (calculated: 145g*13.8%), Baiziren: 12.0g (calculated: 145g*8.3%), Fuling: 15.1g (calculated: 145g*10.4%), Yinghuafen: 12.0g (calculated: 145g*8.3%), Dilong: 20.0g (calculated: 145g*13.8%).
[0019] Preparation process: Step S1 (preparation of mixed medicine powder): The above weighed Danshen, Baiyun, Gualouren, Yuanzhi, Maidong, Tanshen, Qingpi, Baihe, Baiziren, Fuling, Yinghuafen, a total of 11 kinds of medicinal materials, are put into a pulverizer together for crushing, the crushed medicine powder is passed through a 100-mesh sieve, the fine powder passing through the sieve is collected, and is fully mixed and uniform, to obtain mixed medicine powder A, which is sealed for later use; Step S2 (preparation of Dilon powder): Take the weighed Dilon 20.0g, put it in a clean container, add about 4-6g of yellow wine, which is 20%-30% of the mass of Dilon, and mix well, soak for 2-4 hours, until the yellow wine is fully absorbed by the Dilon, put the soaked Dilon in a frying pan, slowly heat with a controlled temperature of 80-120℃, stir-fry until the surface of the Dilon turns dark brown and emits a burnt aroma, then take it out and spread it to cool down, separately pulverize the Dilon after wine frying and cooling, pass through a 100-mesh sieve, to obtain Dilon powder B; Step S3 (mixing and pill making): Put the mixed medicine powder A prepared in step S1 and the Dilon powder B prepared in step S2 into a three-dimensional motion mixer, mix for 30 minutes until completely uniform, to obtain the final medicine powder, add appropriate amount of purified water as a binder to the final medicine powder, stir to make a soft material, use an automatic Chinese medicine pill making machine to make the soft material into spherical pellets with a diameter of about 5mm; Step S4 (drying and packaging): The wet pills are placed in a hot air circulating drying oven and dried at a temperature below 60°C until the moisture content is below 9%. The dried pills are screened to remove irregular ones. Finally, the pills are packaged by an aluminum blister packaging machine according to a single serving amount of 10 pills per plate and 1 plate per time, to obtain the finished product.
[0020] Example 2: Optimization of the preparation process parameters In Example 1, the screening mesh size of steps S1 and S2 can be selected in the range of 80-120 mesh, preferably 100 mesh, which ensures the dissolution rate of the active ingredients and avoids the adverse effects of excessively fine powder on the pill preparation process; in step S4, the drying temperature should be no higher than 60°C to retain the heat-sensitive active ingredients in the medicinal materials.
[0021] Example 3: Quality detection of the pharmaceutical composition To prove the stability and controllability of the medicine of the present application, the following detections are performed on the pills prepared in Example 1: Appearance: The product is brown to black spherical pills; the aroma is slight and the taste is slightly bitter; Identification: The thin layer chromatography is used for qualitative identification of Salvia miltiorrhiza, Ophiopogon japonicus and Poria cocos in the prescription, and the corresponding characteristic spots can be detected; Inspection: The pills meet the relevant provisions of the "Chinese Pharmacopoeia" under the item of pills. The moisture content should not exceed 9.0%, and the pill weight difference limit, dissolution time limit, etc. all meet the provisions; Content determination: The content of salvianolic acid B in Salvia miltiorrhiza is determined by high performance liquid chromatography. It is stipulated that each pill contains no less than 1.5 mg of salvianolic acid B. The determination results of three batches of pilot products meet the provisions, indicating that the process of the present application is stable and the quality is controllable.
[0022] Example 4: Clinical efficacy observation cases Twelve typical heart disease patients using the medicine of the present application are tracked and observed, and all the patients give their informed consent; Treatment method: The pills prepared in Example 1 of the present application are given, and oral administration is performed, 6 pills per time, 3 times a day, about 3g of crude drug per time, and the treatment course is 6-9 months; Observation index: The improvement of the patient's subjective symptoms, electrocardiogram and color Doppler ultrasound examination of the heart, etc.; Efficacy standard: Marked effect: symptoms basically disappear and electrocardiogram returns to normal; effect: symptoms are obviously improved and electrocardiogram is improved; no effect: symptoms and electrocardiogram have no change or aggravation; The results are shown in the following table: Statistical table of clinical recovery of heart disease patients
[0023] Example 5: Further description of the use of the medicine The pharmaceutical composition of the present application can be used for preparing medicine for treating coronary heart disease, myocardial ischemia and arrhythmia. In specific application, for angina pectoris patients, it can effectively reduce the frequency of attack and the degree of pain; for palpitation and flustered patients, it can play the role of nourishing heart and calming the nerves and stabilizing the heart rhythm; under the guidance of doctors, it can be combined with conventional western medicine to play the role of synergistic effect and reducing the dosage of western medicine, and is suitable for the auxiliary treatment of coronary heart disease angina pectoris of the type of qi stagnation and blood stasis.
[0024] The basic principles and main features of the present application and the advantages of the present application are shown and described above. It should be understood by those skilled in the art that the present application is not limited by the above examples, and the above examples and descriptions in the specification are only to illustrate the principles of the present application. Without departing from the spirit and scope of the present application, various changes and improvements can be made to the present application, and these changes and improvements all fall within the scope of the present application. The scope of protection of the present application is defined by the appended claims and their equivalents.
Claims
1. A drug for treating human heart disease, characterized in that: The drug is composed of the following components by mass percentage: Salvia miltiorrhiza 13.8%, Allium macrostemon 4.1%, Trichosanthes kirilowii seed 8.3%, Polygala tenuifolia 2%, Ophiopogon japonicus 8.3%, Santalum album 2%, Citrus reticulata peel 6.9%, Lilium brownii 13.8%, Platycladus orientalis seed 8.3%, Poria cocos 10.4%, Cherry blossom powder 8.3%, and Pheretima aspergillum 13.8%, the sum of the mass percentages of the above components is 100%.
2. The drug for treating human heart according to claim 1, characterized in that: The dosage form of the pharmaceutical composition is pills.
3. A method for preparing a drug for treating human heart disease, used to prepare the drug for treating human heart disease as described in claims 1-2, characterized in that: Includes the following steps: S1: Take the prescribed amounts of Salvia miltiorrhiza, Allium macrostemon, Trichosanthes kirilowii seed, Polygala tenuifolia, Ophiopogon japonicus, Santalum album, Citrus reticulata peel, Lilium brownii, Platycladus orientalis seed, Poria cocos, and Sakura powder respectively, pulverize them, and sieve them to obtain a mixed medicinal powder; S2: Take the prescribed amount of Pheretima aspergillum, stir-fry it with wine, pulverize it, and sieve it to obtain Pheretima aspergillum powder; S3: Thoroughly mix the mixed medicinal powder obtained in step S1 with the Pheretima aspergillum powder obtained in step S2, and make pills using existing pill-making technology.
4. The method for preparing a drug for treating human heart disease according to claim 3, characterized in that: The specific process of stir-frying with wine in step S2 is as follows: mix the earthworm with rice wine, let it soak until the wine is absorbed, stir-fry over low heat until the surface turns brown, and then remove and let it cool.
5. The method for preparing a drug for treating human heart disease according to claim 3, characterized in that: The sieve used for pulverizing and sieving in steps S1 and S2 has a mesh size of 80-120.
6. The method for preparing a drug for treating human heart disease according to claim 3, characterized in that: Following step S3, the process also includes packaging the prepared pills into single-dose doses.